Non-invasive management of infants with SFTPC pathogenic variants

Deborah R Liptzin MD MS^1*, Matthew D. McGraw, MD², Timothy Stidham, MD³, Jennifer A. Wambach, MD, MS⁴, Robin R. Deterding, MD¹

¹Department of Pediatrics, Section of Pulmonary and Sleep Medicine, University of Colorado, Aurora, CO;²Department of Pediatrics, Division of Pulmonology, University of Rochester Medical Center, Rochester, NY;³Department of Pediatrics, Division of Pediatric Critical Care, Logan Health Medical Center, Kalispell, MT;⁴Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine and St. Louis Children’s Hospital, St. Louis, MO.

Funding Sources: DRL has funding from the National Institute of Health UG1OD024952. MDM reports grant support from the National Institute of Environmental Health Sciences (NIEHS) P30ES001247, K08ES033290, and Boehringer Ingelheim (BI) as a scientific advisory committee member for childhood interstitial lung disease. JAW reports grant support from the National Heart, Lung and Blood Institute (R01 HL149853, U01 HL134745) and the Children’s Discovery Institute. TS reports no funding or conflicts of interest. RRD reports the following:

-Now Vitals, CEO and Founder

-Boehringer Ingelheim, Consultant and Coordinating Investigator

-Earables, Founder and Chief Medical Officer

-EvoEndo, Consultant and Founder

-Roche, Inc., Consultant

-The France Foundation, Consultant

*Corresponding Author: Deborah R Liptzin, dliptzin@yahoo.com